Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by normal memory loss and cognitive impairment in humans. Many drug targets and disease-modulating therapies are available for treatment of AD, but none of these are effective enough in reducing problems associated with recognition and memory. Potential drug targets so far reported for AD are β-secretase, γ-secretase, amyloid beta (Aβ) and Aβ fibrils, glycogen synthase kinase-3 (GSK-3), acyl-coenzyme A: cholesterol acyl-transferase (ACAT) and acetylcholinesterase (AChE). Herbal remedies (antioxidants) and natural metal-chelators have shown a very significant role in reducing the risk of AD, as well as lowering the effect of Aβ in AD patients. Researchers are working in the direction of antisense and stem cell-based therapies for a cure for AD, which mainly depends on the clearance of misfolded protein deposits -including Aβ, tau, and alpha-synuclein. Computational approaches for inhibitor designing, interaction analysis, principal descriptors and an absorption, distribution, metabolism, excretion and toxicity (ADMET) study could speed up the process of drug development with higher efficacy and less chance of failure. This paper reviews the known drugs, drug targets, and existing and future therapies for the treatment of AD.
Introduction
. NPT002 is an elongated, ~950
nm long particle that cannot penetrate into the brain from the blood.
AD is characterized by the formation of intracellular neurofibrillary tangles (NFT) and extracellular senile plaques in the brain cortex [5] . NFTs are composed of hyperphosphorylated microtubule-binding protein tau, while the senile plaques are aggregates of 40 to 43 residues of amyloid beta proteins (Aβ40 to Aβ43) [6] derived from proteolytic cleavage of amyloid precursor protein (APP) [7] by β and γ-secretases [8, 9] . Aggregation of Aβ causes neuronal destruction and memory loss [10] , which is associated with oxidative stress, mitochondrial dysfunction, disruption of membrane integrity, abnormal calcium homeostasis, and induction of apoptosis [11] Aβ42 is believed to play a crucial role in the pathogenesis of AD because it is a predominant component of the senile plaques of AD patients [12] , and it is significantly neurotoxic and responsible for aggregation resulting in the formation of Aβ fibrils [13] [14] [15] ; however, Aβ43 also appears to be prone to aggregate in vitro as Aβ42 [16] . For the development of new aggregation inhibitors, the structure and aggregation mechanism of Aβ fibrils has been studied extensively. Aβ fibrils are reported to be 7-12 nm in diameter and are composed of several proto filaments, which are 3-6 nm in diameter [17, 18] . Aβ fibrils in both Aβ40 and Aβ42 have β strands lying perpendicular to the fiber axis and form intermolecular parallel β sheets [19] [20] [21] . Besides the amyloid beta pathway, the misfolding and accumulation of tau protein and alpha synuclein may also be responsible for AD, aggregatedTDP-43 prepared from diseased brains [25] . These results indicate that insoluble TDP-43 has prion-like properties that may play a role in the progression of TDP-43 proteinopathy. P301S tau transgenic mice express mutant human tau protein and develop progressive tau pathology. Anti-tau monoclonal antibodies were used to block seeding activity present in P301S brain lysates [26] . These antibodies markedly reduce the level of hyperphosphorylated, aggregated, and insoluble tau, and also reduce microglial Aβ strains with varying biological activities reminiscent of prion strains [27] .
Neuroin ammation
It is well known that both Aβ fibrils and NFT are main cause of neuroinflammation in AD. Aβ fibrils are frequently associated with reactive astrocytes, activated microglia and neuroinflammatory markers such as interleukin.
Mitogen-activated protein kinase (MAPK) cascades (p38 module) that mainly regulate inflammatory gene expression are activated in microglia and neurons in and around senile Aβ plaques [28] . Aβ-activated glia can produce reactive oxygen species (ROS) and reactive nitrogen species (RNS), and Aβ itself possesses interesting reduction-oxidation properties through its capacity to promote metalcatalyzed reduction-oxidation cycling reactions and ROS production [29] . Thus, an Aβ peptide itself, as well as small oligomeric forms (Aβ fibrils), are inherently neuroinflammatory. Most
NSAIDs were designed to block prostaglandin synthesis through inhibition of cyclooxygenase (COX), and modern selective COX inhibitors can block inducible cyclooxygenase 2 (COX-
Population-based studies suggest that NSAID use may diminish AD risk by 80% if used for more than two years [30] . Several clinical trials were designed to slow progression of AD through administration of NSAIDs, but they failed to produce a clear benefit. Minocycline is a tetracyclic derivative with anti-inflammatory and neuroprotective properties. Minocycline treatment corrects the up-regulation of inducible nitric oxide synthase (NOS) and COX-II levels in young transgenic placebo mice [31] .
Minocycline treatment also restores the levels of BACE1 to normal, which is found to be upregulated in transgenic placebo mice.
Small molecules as inhibitors of Aβ aggregation and misfolding
Small molecules that specifically and efficiently inhibit Aβ aggregation could be used as therapeutic agents for AD. Congo red (CR),
Berberine and its analogues, and β-sheet breaker peptide are well-known inhibitors of Aβ aggregation [32, 33] . CR is a histological dye that binds to Aβ fibrils because of its extensive beta-sheet structure. Binding of CR to Aβ fibrils has been proven by the change in absorbance spectrum of the dye upon binding to Aβ fibrils [34] . Spectroscopic studies reveal that CR likely binds electrostatically to the imidazolium side chains of histidine residues that are exposed on the surface of amyloid fibrils [35] . CR binds to the positively charged surface residues of the Aβ fibril [36] .
(E)-6-Methyl-4′-amino-2-styrylquinoline has been reported as a small molecule with features allowing it to potentially diagnose, deliver therapy and monitor response to therapy in protein misfolding diseases [37] . CR can bind to critical intermediate structural forms of Aβ, and therefore it has been suggested as a potential therapeutic agent against AD [38] . CR interacts with the helical form of Aβ, and the main interaction site is located at the first helical and hydrophobic core region, residues 17-25, which is assigned as a discordant helix region [39] .
This study implies that any factors or molecules that can stabilize the discordant helical conformation may prevent Aβ aggregation.
Dipeptide-derived inhibitors of
BACE1enzyme have shown to be useful in the treatment of AD [40] . L Carnosine (alanylhistidine) protects against the aging processes of the brain by retarding lipid peroxidation and stabilizing cell membranes.
Carnosine is not able to form stable contacts with Aβ, but it has been reported to block the pathway of aggregation by disturbing the hydrogen bonding of residues involved in aggregation [41] . NMR provides new clues about how a dipeptide molecule can block the formation of toxic amyloid beta-peptide aggregates in the mouse brain.
Recent studies have shown that polyphenolic compounds from plants, specifically food products such as green tea, red wine, and curcumin (diferuloylmethane), the yellow pigment in the rhizome of the spice turmeric (Curcuma longa), have potent anti-aggregating activity [42] [43] [44] [45] [46] . Epidemiological studies report that India, where turmeric consumption is widespread, has a lower incidence of AD than the USA [47] . In vitro studies have shown that curcumin not only inhibits Aβ aggregation, but also disaggregates Aβ fibrils [48, 49] .
In vivo studies using AD transgenic mice have shown that dietary curcumin lowers Aβ deposition in the brain, and intravenously injected curcumin crosses the blood-brain barrier and binds to amyloid plaques [50, 51] . is highly expressed in neurons, and it can also be expressed in astrocytes under conditions of chronic stress [69] . BACE1 has maximal activity at an acidic pH; therefore, agents that disrupt intracellular pH inhibit BACE1 activity.
The pH of endosomes (pH 4.0 -5.0) is optimal for β-secretase activity, which explains the requirement of endocytosis for optimal BACE1
function. BACE inhibitors were designed focusing on active-site binding, neglecting the subcellular localization of the active enzyme.
Rajendran and his colleagues addressed this
issue by synthesizing a membrane-anchored version of a BACE transition-state inhibitor by linking it to a sterol moiety [70] . This inhibitor was found to reduce enzyme activity much more efficiently than the free inhibitor in cultured cells and in vivo.
γ-secretase
The γ-secretase enzyme may be a potentially Semagacestat does not improve cognitive status, and patients receiving higher doses had problems with functional ability, skin cancers and infections [77] . 
Aβ and Aβ brils

Glycogen synthase kinase-3 (GSK-3)
The phosphorylated form of tau has been shown to be functionally inactive [83] . A mutation in a splice site of tau was found to be associated with the formation of four-repeat tau. Four-repeat tau that is generated by mutations in the TAU gene has a high capacity to aggregate rapidly. This mutation is linked to a form of dementia with NFT formation in the absence of amyloid deposition. NFT can also lead to neurodegeneration, which suggests that NFT formation may be the cause of neurodegeneration [84] . Secretion [87] . Novel series of 2-(4-pyridyl) thienopyridinone GSK-3 inhibitors were studied and their binding mode, cellular activity and CNS penetration was also determined [88] . Novel series of GSK-3 inhibitors (6-amino-4-(pyrimidin-4-yl) pyridones) were also derived from a high throughput screening [89] . These inhibitors could be a potential drug for AD after meeting the criteria of good potency, selectivity and CNS penetration. This study suggests that acetylcholinesterase inhibitors should be used in preference to Ginkgo biloba for treatment of AD patients [107] . An interaction view of donepezil with AChE has been shown in Figure 6 Tacrine is another AChE inhibitor, but it also has severe side effects on the human body.
Acyl-coenzyme A: cholesterol acyl-transferase
The specificity and activity of Hup A for AChE can be enhanced through pharmacophore 
5'-UTR of APP mRNA
Studies with primary cultures of neuronal cells have shown that NGF, FGF, and IL-1 increase both APP mRNA and promoter levels [120, 121] . Memantine is a non-competitive NMDA antagonist, which blocks NMDA receptormediated excitotoxicity [133] . Memantine only functions in pathophysiological conditions (i.e. NMDA receptor overactivation) and leaves physiological neurotransmission unchanged.
Memantine, an NMDA channel blocker, is an approved pharmacological drug available for the treatment of AD [134, 135] . Pharmacological properties of acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine)
were also studied and tested, but there is still need for more effective therapy for AD.
It is important to design analogues of these inhibitors with high specificity to their target, and their QSAR and ADMET properties must be predicted before synthesis and clinical trial [136] . Cu in the aged hippocampus [143] . It has been observed that impaired regeneration in aged mice is reversible by exposure to young blood products, suggesting that young blood contains a growth differentiation factor (GDF11) that can restore regenerative function [144] . GDF11 is a rejuvenating factor for skeletal muscle. This indicates that GDF11 systemically regulates muscle aging and may be therapeutically useful for reversing age-related skeletal muscle and stem cell dysfunction. This difficulty can be overcome by directly injecting a viral vector encoding a transcriptionbased siRNA into the human brain.
Future perspective
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